Curasight A/S (NGM:CURAS)

Market Cap	1.10B +255.5%
Revenue (ttm)	n/a
Net Income	-77.13M
EPS	-1.59
Shares Out	47.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,349
Average Volume	46,523
Open	16.35
Previous Close	16.45
Day's Range	15.10 - 16.35
52-Week Range	1.80 - 17.85
Beta	0.26
RSI	52.03
Earnings Date	Feb 26, 2026

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. The company develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. It is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CURAS

Financial Performance

Financial numbers in DKK